This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Glaucoma  • Alert me on articles by topic

Alejandro Oliver, MD; Hua Gao, MD, PhD; Darrell WuDunn, MD, PhD; Mohammed O. Peracha, MD; Louis B. Cantor, MD

Arch Ophthalmol. 2006;124:1788-1790.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In recent years, intravitreal triamcinolone acetonide (IVT) injection has emerged as an important therapeutic modality and has been evaluated as treatment of a large range of macular pathologic abnormalities, including cystoid macular edema, choroidal neovascularization, and diabetic macular edema.^1-3 Even though the functional and anatomical improvement observed is promising, in particular when treating macular edema, the therapeutic efficacy is somewhat shadowed by the finding that IVT treatment also results in elevated intraocular pressure (IOP) in approximately 40% of eyes treated.⁴ High baseline IOP and history of glaucoma are associated with greater incidence of post-IVT IOP elevation, and as many as 50% of glaucomatous eyes have been reported to develop an IOP of 24 mm Hg or greater following the procedure.^4-5 This observation has led to a common practice of considering glaucoma . . . [Full Text of this Article]

Report of Cases


Comment

AUTHOR INFORMATION